HomeCompareMRVFF vs ABBV

MRVFF vs ABBV: Dividend Comparison 2026

MRVFF yields 204.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRVFF wins by $134.54M in total portfolio value
10 years
MRVFF
MRVFF
● Live price
204.19%
Share price
$0.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$134.64M
Annual income
$68,573,578.28
Full MRVFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MRVFF vs ABBV

📍 MRVFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRVFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRVFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRVFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRVFF
Annual income on $10K today (after 15% tax)
$17,355.79/yr
After 10yr DRIP, annual income (after tax)
$58,287,541.54/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MRVFF beats the other by $58,266,485.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRVFF + ABBV for your $10,000?

MRVFF: 50%ABBV: 50%
100% ABBV50/50100% MRVFF
Portfolio after 10yr
$67.37M
Annual income
$34,299,175.02/yr
Blended yield
50.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MRVFF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRVFF buys
0
ABBV buys
0
No recent congressional trades found for MRVFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRVFFABBV
Forward yield204.19%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$134.64M$102.3K
Annual income after 10y$68,573,578.28$24,771.77
Total dividends collected$127.03M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MRVFF vs ABBV ($10,000, DRIP)

YearMRVFF PortfolioMRVFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$31,119$20,418.58$11,550$430.00+$19.6KMRVFF
2$92,680$59,382.92$13,472$627.96+$79.2KMRVFF
3$264,456$165,288.68$15,906$926.08+$248.6KMRVFF
4$723,754$440,785.96$19,071$1,382.55+$704.7KMRVFF
5$1,901,825$1,127,408.73$23,302$2,095.81+$1.88MMRVFF
6$4,803,662$2,768,709.08$29,150$3,237.93+$4.77MMRVFF
7$11,675,668$6,535,748.92$37,536$5,121.41+$11.64MMRVFF
8$27,339,353$14,846,388.95$50,079$8,338.38+$27.29MMRVFF
9$61,742,649$32,489,540.64$69,753$14,065.80+$61.67MMRVFF
10$134,638,212$68,573,578.28$102,337$24,771.77+$134.54MMRVFF

MRVFF vs ABBV: Complete Analysis 2026

MRVFFStock

Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA and RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was incorporated in 1983 and is headquartered in Mississauga, Canada.

Full MRVFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MRVFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRVFF vs SCHDMRVFF vs JEPIMRVFF vs OMRVFF vs KOMRVFF vs MAINMRVFF vs JNJMRVFF vs MRKMRVFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.